Drug Profile
Research programme: antibody-based cancer therapies - Medarex/Oxford BioTherapeutics
Alternative Names: OX-003; OX-025Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Medarex; Oxford Genome Sciences
- Developer Oxford BioTherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer; Small cell lung cancer
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in United Kingdom (Parenteral)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in United Kingdom (Parenteral)
- 29 Sep 2017 Alere has been acquired by Abbott Healthcare